Molecular Product Management LLC

Molecular Product Management is a startup focused on diabetic peripheral neuropathy (DPN), the nerve and microvascular damage that causes chronic pain, burning and numbness. Our breakthrough therapy treats nerve damage itself,, unlike current drugs that only kill pain and have serious side effects. At a time when Type 2 diabetes is a global epidemic and 50% of all sufferers develop some degree of DPN, we are answering a vast and unmet need to substantially improve patients' lives. By addressing a core condition, our drug also will deliver value, reducing DPN's long-term social and medical costs. MPM plans to put our drug on an accelerated FDA path through early trials, enabling exit via acquisition in 3-4 years. MPM holds exclusivity and we think the pharma M&A space has great demand for innovative DPN therapies.